Extended Data Table 2 Summary of Adverse Events for Patient 2 (TDT)

From: CRISPR–Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia

  1. *All the grade of AEs was evaluated according to the Common Terminology Criteria forAdverse Events (CTCAE) Version 5.0, which was published on November 27 2017.
Back to article page